A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Not yet recruiting · NCT07833436 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever | Arenaviridae infectious disease, Infections, Lassa fever, RNA Virus Infections, viral hemorrhagic fever, viral infectious disease | Not yet recruiting | Phase 1 | 2026-09-25 | NCT07833436 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institut Pasteur | 54 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre d'Investigation Clinique en Vaccinologie Cochin-Pasteur | Paris | France | 1 |